Apatinib - LSK Biopharma

Drug Profile

Apatinib - LSK Biopharma

Alternative Names: AiTan; Apatinib mesylate; YN-968-D1

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Bukwang Pharmaceutical; Fudan University Shanghai Cancer Center; Jiangsu Hengrui Medicine Co.; LSK Biopharma
  • Class Amides; Antineoplastics; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Solid tumours
  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 14 Aug 2017 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease) in China (NCT03245307)
  • 02 Jun 2017 Phase-I clinical trials in Gastric cancer (In volunteers) in USA (PO) before June 2017
  • 02 Jun 2017 Pharmacokinetics data from a phase I trial in Gastric cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top